gatifloxacin has been researched along with Bacterial Infections, Gram-Positive in 16 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
| Excerpt | Relevance | Reference |
|---|---|---|
| "3% gatifloxacin ophthalmic solution in preventing bacterial endophthalmitis in rabbits." | 3.74 | Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits. ( Kozai, S; Ohashi, Y; Sakaki, H; Suzuki, T; Tajika, T; Wada, T, 2008) |
| "To evaluate the ocular surface and aqueous antimicrobial effects of gatifloxacin and moxifloxacin administered in two dosing regimens to patients undergoing phacoemulsification." | 2.73 | Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery. ( Amico, LM; Bucci, FA; Evans, RE, 2008) |
| "Gatifloxacin showed lower resistance levels than moxifloxacin." | 1.38 | [In vitro antibiotic susceptibility to fluoroquinolones]. ( Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA, 2012) |
| "Gatifloxacin was more potent than either ciprofloxacin or levofloxacin against all Gram-positive species." | 1.30 | Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers. ( Diekema, DJ; Jones, RN; Rolston, KV, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huband, MD | 1 |
| Cohen, MA | 1 |
| Zurack, M | 1 |
| Hanna, DL | 1 |
| Skerlos, LA | 1 |
| Sulavik, MC | 1 |
| Gibson, GW | 1 |
| Gage, JW | 1 |
| Ellsworth, E | 1 |
| Stier, MA | 1 |
| Gracheck, SJ | 1 |
| Koh, JJ | 2 |
| Lin, S | 2 |
| Aung, TT | 2 |
| Lim, F | 2 |
| Zou, H | 2 |
| Bai, Y | 1 |
| Li, J | 2 |
| Lin, H | 1 |
| Pang, LM | 1 |
| Koh, WL | 1 |
| Salleh, SM | 1 |
| Lakshminarayanan, R | 2 |
| Zhou, L | 1 |
| Qiu, S | 1 |
| Pervushin, K | 1 |
| Verma, C | 2 |
| Tan, DT | 2 |
| Cao, D | 2 |
| Liu, S | 2 |
| Beuerman, RW | 2 |
| Wang, L | 1 |
| Wang, Y | 1 |
| Ren, L | 1 |
| Coburn, PS | 1 |
| Miller, FC | 1 |
| LaGrow, AL | 1 |
| Land, C | 1 |
| Mursalin, H | 1 |
| Livingston, E | 1 |
| Amayem, O | 1 |
| Chen, Y | 1 |
| Gao, W | 1 |
| Zhang, L | 1 |
| Callegan, MC | 2 |
| Tsuchiya, Y | 1 |
| Kobayakawa, S | 1 |
| Tsuji, A | 1 |
| Tochikubo, T | 1 |
| Reddy, AK | 1 |
| Garg, P | 1 |
| Alam, MR | 1 |
| Gopinathan, U | 1 |
| Sharma, S | 1 |
| Krishnaiah, S | 1 |
| Yamamoto, S | 1 |
| Akiyama, K | 1 |
| Yoshimoto, T | 1 |
| Kanokogi, M | 1 |
| Yabumoto, H | 1 |
| Ihara, H | 1 |
| Ishikawa, E | 1 |
| Yoshioka, M | 1 |
| Kokura, K | 1 |
| Shima, H | 1 |
| Wong, CA | 1 |
| Galvis, V | 1 |
| Tello, A | 1 |
| Villareal, D | 1 |
| Rey, JJ | 1 |
| Dubreuil, L | 1 |
| Behra-Miellet, J | 1 |
| Neut, C | 1 |
| Calvet, L | 1 |
| Bucci, FA | 1 |
| Amico, LM | 1 |
| Evans, RE | 1 |
| Wiskur, BJ | 1 |
| Robinson, ML | 1 |
| Farrand, AJ | 1 |
| Novosad, BD | 1 |
| Wada, T | 1 |
| Kozai, S | 1 |
| Tajika, T | 1 |
| Sakaki, H | 1 |
| Suzuki, T | 1 |
| Ohashi, Y | 1 |
| Jones, RN | 2 |
| Beach, ML | 1 |
| Pfaller, MA | 1 |
| Doern, GV | 1 |
| Diekema, DJ | 1 |
| Rolston, KV | 1 |
| Blondeau, JM | 1 |
| Laskowski, R | 1 |
| Bjarnason, J | 1 |
| Stewart, C | 1 |
| Garcia Sánchez, JE | 1 |
| Fresnadillo Martínez, MJ | 1 |
1 trial available for gatifloxacin and Bacterial Infections, Gram-Positive
| Article | Year |
|---|---|
Antimicrobial efficacy of prophylactic gatifloxacin 0.3% and moxifloxacin 0.5% in patients undergoing phacoemulsification surgery.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Antitubercular Agents; Aqueous Humor; Aza Compounds; | 2008 |
15 other studies available for gatifloxacin and Bacterial Infections, Gram-Positive
| Article | Year |
|---|---|
In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant gram-positive and fastidious organism groups.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Resistance, Multiple; Gram-Positive Bacteria | 2007 |
Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
Topics: Amino Acids; Animals; Anti-Bacterial Agents; Cell Membrane; Drug Resistance, Multiple, Bacterial; Gr | 2015 |
Symmetrically Substituted Xanthone Amphiphiles Combat Gram-Positive Bacterial Resistance with Enhanced Membrane Selectivity.
Topics: Animals; Anti-Bacterial Agents; Cornea; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Pos | 2017 |
Disarming Pore-Forming Toxins with Biomimetic Nanosponges in Intraocular Infections.
Topics: Animals; Bacterial Toxins; Biomimetic Materials; Erythrocytes; Eye Infections, Bacterial; Gatifloxac | 2019 |
Preventive effect against post-cataract endophthalmitis: drug delivery intraocular lens versus intracameral antibiotics.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Aqueous Humor; Biological Availability; Cataract E | 2008 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinol | 2010 |
Clinical efficacy of oral administration of 200 mg gatifloxacin once daily for 3 days for the treatment of patients with uncomplicated cystitis.
Topics: Adult; Anti-Infective Agents; Cystitis; Drug Administration Schedule; Female; Fluoroquinolones; Gati | 2009 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; | 2012 |
In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; | 2003 |
Toward improving therapeutic regimens for Bacillus endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Bacillus cereus; Biological Availability; Dexamethasone; Disease Mod | 2008 |
Prophylactic efficacy of ophthalmic quinolones in experimental endophthalmitis in rabbits.
Topics: Animals; Anterior Chamber; Anti-Bacterial Agents; Biological Availability; Disease Progression; Endo | 2008 |
Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America.
Topics: Anti-Infective Agents; Antitubercular Agents; Bacteriological Techniques; Ciprofloxacin; Drug Resist | 1998 |
Antimicrobial activity of gatifloxacin compared to seven other compounds tested against gram-positive organisms isolated at 10 cancer-treatment centers.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cancer Care Facilities; Drug Resistance, Microbial; Fl | 1999 |
Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms.
Topics: Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gr | 2000 |
[Novel antibiotics active against Gram-positive bacteria].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Drug Resistance, Microbial; Drug Therap | 2000 |